Evaluation of sputum eosinophil count as a predictor of treatment response to mepolizumab

In patients with severe eosinophilic asthma and sputum eosinophil counts of ≥3–<30%, sputum eosinophils may not represent a more useful biomarker than blood eosinophils for predicting clinical treatment response to mepolizumab https://bit.ly/3pOTw93

Detalles Bibliográficos
Autores principales: Pavord, Ian D., Buhl, Roland, Kraft, Monica, Prazma, Charlene M., Price, Robert G., Howarth, Peter H., Yancey, Steven W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Respiratory Society 2022
Materias:
Research Letters
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9062111/
https://www.ncbi.nlm.nih.gov/pubmed/35509441
http://dx.doi.org/10.1183/23120541.00560-2021

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9062111/
https://www.ncbi.nlm.nih.gov/pubmed/35509441
http://dx.doi.org/10.1183/23120541.00560-2021

Ejemplares similares